<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521482</url>
  </required_header>
  <id_info>
    <org_study_id>TMZ/05</org_study_id>
    <secondary_id>P04932</secondary_id>
    <nct_id>NCT00521482</nct_id>
  </id_info>
  <brief_title>Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma</brief_title>
  <official_title>Intensive Dose Temozolomide Treatment or Temozolomide With Thalidomide Treatment in Recurrent Glioblastoma After Standard Therapy:a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of intensive dose temozolomide&#xD;
      treatment alone in parallel to a combination with thalidomide in patients with recurrent&#xD;
      glioblastoma after standard therapy.&#xD;
&#xD;
      In the treatment arm A of the study it will be investigated whether or not continuous dosing&#xD;
      of temozolomide may overcome alkylator resistance in patients with glioblastoma who progress&#xD;
      on the 5/28 day dosing regimen.&#xD;
&#xD;
      For treatment arm B it is postulated that the combination of thalidomide and temozolomide is&#xD;
      effective with respect to time to progression and progression-free survival due to the fact&#xD;
      that temozolomide and thalidomide have different mechanisms of action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Primary objectives: To determine the proportion of patients with progression- free&#xD;
           survival after 6 months of intensive dose temozolomide treatment alone or in combination&#xD;
           with thalidomide in patients with recurrent glioblastoma multiforme after standard&#xD;
           therapy.&#xD;
&#xD;
        -  Secondary objectives: To assess the effects on tumor growth. To determine the time to&#xD;
           disease progression. To determine the proportion of patients with progression- free&#xD;
           survival. To assess the safety of intensive dose temozolomide treatment alone or in&#xD;
           combination with thalidomide.&#xD;
&#xD;
        -  Explorative evaluations: To assess health related Quality of Life. To assess cognitive&#xD;
           functioning. To compare the two treatment arms in terms of efficacy and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with progression free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a clinical response. Time to disease progression. Progression free survival.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temozolomide 75 mg/m2 daily for 21 days during each 28-day cycle until tumor progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide 200 mg/m2 for 5 days during each 28-day cycle plus Thalidomide 100 mg for 2 weeks, thereafter 200 mg daily continuously until tumor progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide plus Thalidomide</intervention_name>
    <arm_group_label>B</arm_group_label>
    <other_name>Temodal</other_name>
    <other_name>plus</other_name>
    <other_name>Myrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients 18 to 70 years&#xD;
&#xD;
          2. Histologically proven glioblastoma, WHO grade IV&#xD;
&#xD;
          3. Evidence of tumor recurrence or progression by MRI at least 3 months after radiation&#xD;
             treatment&#xD;
&#xD;
          4. Prior radiation treatment with 60 Gy in 2-Gy fractions; concurrent daily temozolomide&#xD;
             75 mg/m2 daily for 42 days (max. 49 days); adjuvant temozolomide 150 - 200mg/m2 for 5&#xD;
             days during each 28-day cycle (max. 6 cycles)&#xD;
&#xD;
          5. Patient should have received a minimum of 2 cycles of adjuvant chemotherapy with&#xD;
             temozolomide after concomitant regime of temozolomide and Radiotherapy&#xD;
&#xD;
          6. Patient had recovered from the effects of surgery&#xD;
&#xD;
          7. Karnofsky Performance Status of ≥70&#xD;
&#xD;
          8. Mini-Mental State Examination score &gt;25&#xD;
&#xD;
          9. Adequate hepatic function: AST &lt;52 U/l, ALT &lt;50 U/l, AP ≤129 U/l&#xD;
&#xD;
         10. Adequate hematological values: neutrophils ≥1.5 x 109/l, thrombocytes ≥100 x 109/l&#xD;
&#xD;
         11. Adequate renal function: clearance &lt;110 μmol/l&#xD;
&#xD;
         12. Written informed consent before entering the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other severe underlying diseases&#xD;
&#xD;
          2. Significant renal, hepatic or bone marrow impairment&#xD;
&#xD;
          3. Pregnant women, women who are breast feeding, and women of childbearing potential who&#xD;
             are not using chemical or mechanical contraception (prescription oral contraceptives,&#xD;
             abstinence, condoms with spermicide, surgical sterilization, diaphragm with&#xD;
             spermicide, or intrauterine device) or have a positive pregnancy test&#xD;
&#xD;
          4. Known Acquired Immune Deficiency Syndrome (AIDS)&#xD;
&#xD;
          5. Known hypersensitivity to temozolomide, dacarbazine or thalidomide (or any of the&#xD;
             excipients)&#xD;
&#xD;
          6. Any concomitant drugs contraindicated for use with temozolomide (according to the&#xD;
             product information in the Swiss drug compendium) and thalidomide (investigator's&#xD;
             brochure, international product information).&#xD;
&#xD;
          7. Concurrent treatment with other experimental drugs or other anti-cancer therapy;&#xD;
             treatment within a clinical trial within 30 days prior to trial entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miroslava Bjeljac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miroslava Bjeljac, MD</last_name>
    <phone>0041 44 255 23 96</phone>
    <email>Miroslava.Bjeljac@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Zurich, Departement of Neurosurgery</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <investigator>
      <last_name>Miroslava Bjeljac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>August 27, 2007</last_update_submitted>
  <last_update_submitted_qc>August 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2007</last_update_posted>
  <keyword>recurrent</keyword>
  <keyword>after standard therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

